

Brainstorm Cell Therapeutics: (BCLI.OB) - an emerging company developing adult stem cell therapeutic products derived from autologous (*the patient own*) bone marrow cells for the treatment of neurodegenerative diseases. Brainstorm's NurOwn patent pending technology is based on discoveries made by the scientific team led by Professor Eldad Melamed, Head of Neurology at Rabin Medical Center, and Dr. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. The technology allows for the differentiation of bone marrow-derived stem cells into functional neurons and astrocytes, as demonstrated in animal models.

The company holds rights to develop and commercialize the technology through an exclusive worldwide licensing agreement with Tel-Aviv University. The Company's initial focus is on Parkinson's Disease, ALS and Spinal Cord Injury, although its technology has promise for treating several other diseases including MS, Huntington's disease and stroke.